(Q30381722)

21 June 2017

title

Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. (English)

1 reference

21 June 2017

1 reference

1 reference

11

Young Chul Sung

1 reference

21 June 2017

Ki Seok Park

1

1 reference

21 June 2017

Jiyeung Lee

2

1 reference

21 June 2017

So Shin Ahn

3

1 reference

21 June 2017

Young-Ho Byun

4

1 reference

21 June 2017

Baik Lin Seong

5

1 reference

21 June 2017

Yun Hee Baek

6

1 reference

21 June 2017

Min-Suk Song

7

1 reference

21 June 2017

Young Ki Choi

8

1 reference

21 June 2017

Yun Jeong Na

9

1 reference

21 June 2017

Inhwan Hwang

10

1 reference

21 June 2017

Chang Geun Lee

12

1 reference

21 June 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

21 June 2017

1 reference

21 June 2017

volume

395

1 reference

21 June 2017

issue

2

1 reference

21 June 2017

page(s)

182-189

1 reference

Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Development of nonhuman adenoviruses as vaccine vectors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Efficacy of two H5N9-inactivated vaccines against challenge with a recent H5N1 highly pathogenic avian influenza isolate from a chicken in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Human memory CTL response specific for influenza A virus is broad and multispecific

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Avian influenza--a challenge to global health care structures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

New pre-pandemic influenza vaccines: an egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Strategies for developing vaccines against H5N1 influenza A viruses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met as a novel adjuvant for DNA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Isolation and genetic characterization of H5N2 influenza viruses from pigs in Korea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Internal ribosome entry site biology and its use in expression vectors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Cytotoxic T-cell immunity to influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Protective avian influenza in ovo vaccination with non-replicating human adenovirus vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Protection of chickens against avian influenza with non-replicating adenovirus-vectored vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Probable person-to-person transmission of avian influenza A (H5N1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

inferred from DOI database lookup

7 January 2021

based on heuristic

Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2009.09.018

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2009.09.018

1 reference

21 June 2017

1 reference